In its upcoming report, TransMedics (TMDX) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year.
Despite a Q3 earnings miss and short-seller allegations, TMDX has shown remarkable five-year growth and operational advantages. TMDX's market share in heart, liver, and lung transplants has ...